Ketamine / Ketamine-Assisted Therapy

Overview

What It Is Ketamine, at sub-anesthetic doses, can produce rapid antidepressant effects in many people with treatment-resistant depression. Esketamine (Spravato) is an FDA-approved nasal formulation; other routes (IV, intramuscular, oral) are used in specialized clinics. Treatment usually involves a series of supervised sessions, sometimes combined with psychotherapy.

How It Works Ketamine affects glutamate signaling and can rapidly increase synaptic plasticity in mood-related circuits—essentially opening a window in which new connections form more easily. Psychotherapy during or after sessions may help consolidate more adaptive patterns while that window is open. Effects often require repeated administration and ongoing care.

Conditions - FDA-approved: treatment-resistant depression (esketamine/Spravato, with specific protocols). - Also used in clinics for: other depression presentations, some pain conditions, and trauma-related symptoms (off-label or emerging). - Note: Dissociation and blood-pressure changes require monitoring. Medical screening is essential.

How it is administered

Supervised sessions in a clinic using IV, intramuscular, nasal (esketamine/Spravato), or other routes. A series of sessions is typical; some programs include concurrent psychotherapy.

Conditions connected in the NPA database

The NPA Treatment Database lists this treatment in connection with 5 condition records. A database relationship does not establish effectiveness, safety, or suitability for an individual.

• Clinical Depression
• Persistent Pain
• Post Traumatic Stress Disorder (PTSD)
• Migraine & Headaches
• Addiction

Related questions

These controlled question pages reference this treatment through stored condition relationships.

• What treatments are listed for Addiction in the NPA database?
• What treatments are listed for Clinical Depression in the NPA database?
• What treatments are listed for Migraine & Headaches in the NPA database?
• What treatments are listed for Persistent Pain in the NPA database?
• What treatments are listed for Post Traumatic Stress Disorder (PTSD) in the NPA database?

Symptoms connected in the NPA database

The current record associates this treatment with the following symptom information. This is not a claim that the treatment will improve these symptoms.

Practical information

Results and outcomes described in the source record

Rapid mood effects often within hours to days; maintenance varies.

Side effects and risks

Dissociation, blood pressure changes, bladder concerns with frequent use, potential for misuse.

Research context in the NPA database

Research summary

Evidence Level: Strong (for treatment-resistant depression)

What the research shows: Multiple trials show that ketamine (and FDA-approved esketamine) can rapidly reduce depressive symptoms in people who have not responded to other treatments. Effects often require ongoing or repeated administration.

Key takeaway: A medically supervised option for treatment-resistant depression that can work faster than traditional antidepressants for some people.

Research detail

Overview Ketamine, at sub-anesthetic doses, produces rapid antidepressant effects in many people with treatment-resistant depression and is also being studied for certain pain and trauma-related conditions. Esketamine (Spravato) is an FDA-approved nasal formulation for treatment-resistant depression; other routes (IV, intramuscular, oral) are used in specialized clinics. Treatment usually involves a series of supervised sessions, sometimes combined with psychotherapy (ketamine-assisted therapy). Monitoring of blood pressure, dissociation, and other side effects is standard.

Evidence Base and Published Work • Multiple randomized controlled trials and pivotal studies demonstrate that ketamine (and FDA-approved esketamine/Spravato) can rapidly reduce depressive symptoms in treatment-resistant depression. • Systematic reviews confirm short-term efficacy; longer-term strategies, optimal dosing, and the contribution of concurrent psychotherapy continue to be refined. • Key published work includes: – Multiple RCTs and pivotal trials for treatment-resistant depression. – Esketamine (Spravato) FDA-approved data. – Systematic reviews of ketamine and esketamine. – Dissociation, blood-pressure changes, and bladder concerns with frequent use are recognized side effects. Medical screening and supervised administration are essential.

Outcomes Outcomes most frequently described include rapid mood effects, often within hours to days, for treatment-resistant depression. Evidence is strong for short-term antidepressant effects. Effects often require ongoing or repeated administration.

Questions to ask a provider

1. Is ketamine or esketamine (Spravato) appropriate for my treatment-resistant depression or other indication? 2. Will treatment be IV, intramuscular, nasal (Spravato), or oral, and in what setting with what monitoring? 3. How many sessions are typically needed, and is concurrent psychotherapy (ketamine-assisted therapy) included? 4. What are the short-term side effects (dissociation, blood-pressure changes) and any longer-term considerations? 5. Is this covered by insurance for my diagnosis, and what prior authorization is required?